Anbio Biotechnology Class A Ordinary Shares (NNNN) is a publicly traded Healthcare sector company. As of May 21, 2026, NNNN trades at $31.00 with a market cap of $1.24B and a P/E ratio of 0.00. NNNN moved +2.57% today. Year to date, NNNN is -6.90%; over the trailing twelve months it is +298.00%. Its 52-week range spans $5.18 to $55.65. Rallies surfaces NNNN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Anbio CEO to Present Product Pipeline and Strategy at March 18 Healthcare Forum: Anbio Biotechnology's CEO will join a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026, presenting business updates, strategic initiatives, and product development plans. The company highlights its global IVD portfolio spanning infectious disease to pharmacogenomics, aiming to advance rapid diagnostics and expand investor engagement.
| Metric | Value |
|---|---|
| Price | $31.00 |
| Market Cap | $1.24B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $55.65 |
| 52-Week Low | $5.18 |
| Volume | 110 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
NNNN analyst coverage data. Average price target: $0.00.